PREDICTION OF THE INFLUENCE OF ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS OF SECONDARY PREVENTION IN PATIENTS WITH CHRONIC TYPES OF ISCHEMIC HEART DISEASE

Aim. To study therapeutic equivalence of rosuvastatin generic and original medication and to conduct the pharmacoeconomic analysis to compare the impact of the drug on direct expenses in secondary prevention for the patients with chronic ischemic heart disease (CHD). Material and methods. The open label, prospective observational study performed with the switch of medication, that included 38 patients with chronic CHD and duration of 6 months. During 3 months the patients received original drug rosuvastatin Crestor 10-20 mg, leading to the target level of low density cholesterol <1,8 mmol/L. Then the switch done, and generic drug prescribed for 3 months — Rosart (Actavis) in analogous doses. Patients were investigated at the baseline, in 3 and 6 months. Lipid spectrum parameters were measured, C-reactive protein, transaminases and creatinekinase, bilirubin, glucose, creatinine. Evaluation of clinical and economic efficacy of original and generic rosuvastatine was done by modelling. The direct medical expenses were calculated for the usage of medical resources for emergent, outpatient and inpatient care for cardiovascular pathology. For the forecast of cardiovascular events probability and their consequences with associated direct medicalexpenses by the period of time using various therapeutic strategies we used Markov model developed by Belousov et al. (2011). Results. Generic drug Rosart does not show minority by hypolipidemic, anti-inflammatory effects and safety criteria comparing to the original Crestor. Short-term (1 year) prescription of rosuvastatin (Rosart and Crestor equally) increases life duration by 0,99 years; middle-term (5 years) by 4,25 years; long-term (10 years) — by 6,82 and 6,85 years, respectively. Conclusion. The main result of the modelled pharmacoeconomic analysis of the influence of generic and original rosuvastatin on the direct and indirect medical expenses for secondary prevention in chronic ischemic heart disease is a conclusion that the most effective for expenses in the aim-fulfillment is generic rosuvastatin.

rosuvastatin, stable ischemic heart disease, therapeutic equivalence, pharmacoeconomic analysis

1. Diagnostics and correction of lipid disorders for the prevention and treatment of atherosclerosis. Russian recommendations, V review. Russ J Cardiol 2012; 4 (96): 1-32, Suppl. 1. Russian (Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза, V пересмотр. Российский кардиологический журнал 2012; 4 (96): 1-32, приложение 1).

2. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). ESC. Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*et al. Eur Heart J 2012; 33: 1635-701.

3. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the ACС Heart Association Task Force on Practice Guidelines Neil J. Stone et al Circulation. published online November 12, 2013.

4. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low-densitylipoprotein cholesterol, ischemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326, 28 JUNE: 1423-7.

5. Palmer M, Nicholls SJ, Lundman P, et al. Estimating the reduction in 10-year atherosclerotic cardiovascular disease risk with statin therapy: A VOYAGER metaanalysis. Atherosclerosis, July 2015; 241(1): e21-22.

6. Špinar J, Špinarová L, Vítovec J. IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (studie IMPROVE-IT)].Vnitr Lek. 2014 Dec;60(12):1095-101.

7. Oganov RG, Kukharchuk VV, Arutyunov GP, et al on behalf of the DYSIS Study Group. Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Cardiovascular Therapy and Prevention 2012; 11 (4): 70-8. Russian (Оганов Р. Г., Кухарчук В. В., Арутюнов Г. П., и др. от имени исследователей DYSIS. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в российской федерации (российская часть исследованияDYSIS). Кардиоваскулярная терапия и профилактика 2012; 11 (4): 70-8).

8. Karlson BW, Palmer MK, Nicholls SJ, et al. To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? Atherosclerosis 2015;241(2):450-4.

9. Tarlovskaya EI. Generic and original drugs: look practitioner. Russian Medical Journal 2008; 5: 333-7. Russian (Тарловская Е. И. Генерики и оригинальные препараты: взгляд практического врача. Русский медицинский журнал 2008; 5: 333-7).

10. Tarlovskaya EI. Generics in clinical practice. Hypertension 2009; 4: 512-5. Russian (Тарловская Е. И. Генерики в реальной клинической практике. Артериальная гипертония 2009; 4: 512-5).

11. Tarlovskaya EI, Balandina YA, Sapozhnikov IE, Maximchuk NS. Comparative efficacy and safety of lipid-lowering therapy original and generic simvastatin. Rational Pharmacotherapy in Cardiology 2011;7(5): 579-83. Russian (Тарловская Е.И., Баландина Ю. А., Сапожникова И. Е., Максимчук Н. С. Сравнительная эффективность и безопасность гиполипидемической терапии оригинальным и генерическим симвастатином. Рациональная фармакотерапия в кардиологии 2011; 7(5): 579-83).

12. Kutishenko NP, Yakusevich VV, Deev AD, Martsevich SYu. Assessment of the therapeutic equivalence of the brand indapamide and generic indapamide for the treatment of hypertensive patients using a randomized, crossover study. Rational Pharmacotherapy in Cardiology 2007; 2(3): 26-30. Russian (Кутишенко Н. П., Якусевич В. В., Деев А. Д., Марцевич С. Ю. Оценка терапевтической эквивалент- ности оригинального индапамида и индапамида-дженерика убольных артериальной гипертонией с помощью рандомизированного перекрестного исследования. Рациональная фармакотерапия в кардиологии 2007; 2(3): 26-30).

13. Industry Standard “Clinical and economic studies. General Provisions” 91500.14.0001-2002. Appendix to the Order of the Russian N 163 of May 27, 2002.

14. Belousov DY, Afanasiev EV, Beketov AS, Belousov YB. Predicting the effects of statins on direct medical costs for secondary prevention in patients at the high risk for cardiovascular disease. Good clinical practice 2011; 1: 97-115. Russian (Белоусов Д.Ю., Афанасьева Е.В., Бекетов А. С., Белоусов Ю. Б. Прогнозирование влияния статинов на прямые медицинские затраты при вторичной профилактике у пациентов с высоким риском развития сердечнососудистых заболеваний. Качественная клиническая практика 2011; 1: 97-115).

15. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007; 11 (14): 1-160.

16. Grakovich AA, Brow IV, Reutskaya LA, et al. The procedure for conducting clinicoeconomical studies. Minsk, 2008.

17. http://int.imshealth.com/fexp.html. [29.06.2015].

18. Kobalava JD, Villevalde SV. Formation adherence lipid-lowering drugs. http://www. cardiosite.info/articles/article.aspx?articleid=10431, [25.04.2015].

19. Federal State Statistics Service//www.gks.ru. [25.04.2015].

20. Yagudin RI, Kulikov AYu, Litvinenko MM. QALY: History, methodology and future of the method. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology 2010; 1: 7-11. Russian (Ягудина Р.И., Куликов А.Ю., Литвиненко М. М. QALY: История, методология и будущее метода. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология 2010; 1: 7-11).